The MESSINA trial of biologic drug Fasenra (benralizumab) to treat EoE in patients aged 12+ has met one of its dual-primary endpoints but not the second.

At Week 24 of the study, the drug demonstrated a statistically-significant improvement in histological disease remission compared to placebo, but did not show to improve dysphagia symptoms.

MESSINA has 192 centres participating around the globe including the United Kingdom, USA, France, Spain, Germany, Italy, Israel, Netherlands, Russia and Poland. Learn more about the study and endpoints.

Results from the study will be presented at an upcoming medical meeting.

Links

• AstraZeneca press release
• ClinicalTrials.gov listing